Physician profile
Ara Kayayan
NPI 1205828316
$10,853.16
in general payments reported to CMS, 2019-2025
55 companies · $2,239 in 2025
The $2,239 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $1,154 · 2021: $1,665 · 2022: $1,452 · 2023: $1,652 · 2024: $1,773 · 2025: $2,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,663.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,848.94 | 2019-2025 | |
| Novo Nordisk INC | $1,060.87 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $978.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $667.00 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.05 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $554.58 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $450.85 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $413.16 | 2019-2025 | Evenity, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.24 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $260.45 | 2019-2023 | Xarelto |
| Abbott Laboratories | $259.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $233.71 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $216.97 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Allergan, INC. | $214.67 | 2019-2020 | |
| Exact Sciences Corporation | $185.04 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ara Kayayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.